Harrow, Inc. Operating Lease, Payments
Harrow, Inc. (HROW) reported Operating Lease, Payments of $1.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-02
- Harrow, Inc. operating lease, payments for the quarter ending 2025-12-31 was $329.00K, a 0.00% change year-over-year.
- Harrow, Inc. operating lease, payments for the quarter ending 2025-09-30 was $332.00K, a 1.53% increase year-over-year.
- Harrow, Inc. operating lease, payments for the quarter ending 2025-06-30 was $227.00K, a 30.58% decline year-over-year.
- Harrow, Inc. operating lease, payments for the quarter ending 2025-03-31 was $281.00K, a 14.07% decline year-over-year.
- Harrow, Inc. operating lease, payments for fiscal 2025 was $1.17M, a 10.15% decline from fiscal 2024.
- Harrow, Inc. operating lease, payments for fiscal 2024 was $1.30M, a 5.69% increase from fiscal 2023.
- Harrow, Inc. operating lease, payments for fiscal 2023 was $1.23M, a 33.08% increase from fiscal 2022.
- Harrow, Inc. operating lease, payments for fiscal 2022 was $925.00K, a 7.50% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $661.00K derived: sum of 2 quarters · filed 2026-03-02 | $888.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.17M 10-K · filed 2026-03-02 |
| 2025-09-30 | $332.00K 10-Q · filed 2025-11-10 | $559.00K derived: sum of 2 quarters · filed 2025-11-10 | $840.00K 10-Q · filed 2025-11-10 | $1.17M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $227.00K 10-Q · filed 2025-08-11 | $508.00K 10-Q · filed 2025-08-11 | $837.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.16M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $281.00K 10-Q · filed 2025-05-08 | $610.00K derived: sum of 2 quarters · filed 2026-03-02 | $937.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.26M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $656.00K derived: sum of 2 quarters · filed 2026-03-02 | $983.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.30M 10-K · filed 2026-03-02 |
| 2024-09-30 | $327.00K 10-Q · filed 2025-11-10 | $654.00K derived: sum of 2 quarters · filed 2025-11-10 | $972.00K 10-Q · filed 2025-11-10 | $1.29M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $327.00K 10-Q · filed 2025-08-11 | $650.00K 10-Q · filed 2025-08-11 | $964.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $327.00K 10-Q · filed 2025-05-08 | $637.00K derived: sum of 2 quarters · filed 2026-03-02 | $947.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.25M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $620.00K derived: sum of 2 quarters · filed 2026-03-02 | $926.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.23M 10-K · filed 2026-03-02 |
| 2023-09-30 | $310.00K 10-Q · filed 2024-11-14 | $616.00K derived: sum of 2 quarters · filed 2024-11-14 | $921.00K 10-Q · filed 2024-11-14 | $1.23M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $306.00K 10-Q · filed 2024-08-07 | $611.00K 10-Q · filed 2024-08-07 | $915.00K derived: sum of 3 quarters · filed 2024-08-07 | $1.16M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $306.00K 10-Q · filed 2024-05-13 | $609.00K derived: sum of 2 quarters · filed 2024-05-13 | $858.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.06M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $552.00K derived: sum of 2 quarters · filed 2024-03-19 | $759.00K derived: sum of 3 quarters · filed 2024-03-19 | $925.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $249.00K 10-Q · filed 2023-11-13 | $456.00K derived: sum of 2 quarters · filed 2023-11-13 | $622.00K 10-Q · filed 2023-11-13 | $870.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $207.00K 10-Q · filed 2023-08-09 | $373.00K 10-Q · filed 2023-08-09 | $621.00K derived: sum of 3 quarters · filed 2023-08-09 | $871.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $166.00K 10-Q · filed 2023-05-11 | $414.00K derived: sum of 2 quarters · filed 2023-05-11 | $664.00K derived: sum of 3 quarters · filed 2023-05-11 | $915.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $498.00K derived: sum of 2 quarters · filed 2023-03-23 | $749.00K derived: sum of 3 quarters · filed 2023-03-23 | $1.00M 10-K · filed 2023-03-23 |
| 2021-09-30 | $250.00K 10-Q · filed 2022-11-14 | $501.00K derived: sum of 2 quarters · filed 2022-11-14 | $752.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $251.00K 10-Q · filed 2022-08-09 | $502.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $251.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.05M 10-K · filed 2022-03-10 | |||
| 2019-12-31 | $905.00K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |